Drug intelligence / Profile preview

ONM-401

Development stage: Preclinical
Lead developer: OncoNano Medicine, Inc.
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**ONM-401** is a monoclonal antibody in preclinical development for oncology, specifically targeting neoplasms. Developed by OncoNano Medicine, Inc., it is listed under immunology applications in oncology contexts, potentially leveraging immune-mediated mechanisms, though specific indications and detailed therapeutic profiles remain undisclosed in available data.[5][9]

Beyond the preview

Go deeper on ONM-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONM-401.

Explore the full profile